CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 174 enrolled
Drug / intervention
ALVAC-HIV (vCP1452) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00076063
NCT00076063Phase 2Completed
CompareCT.gov

A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jan 14, 2004·Updated Oct 14, 2021

In Brief

A Phase 2 clinical trial evaluating ALVAC-HIV (vCP1452) and LIPO-5 for HIV Infections. Completed, enrolled 174 participants across 11 sites.

Detailed Summary

This study will test the immune system response to and safety of two HIV vaccines alone and in combination: ALVAC-HIV (vCP1452) and LIPO-5. ALVAC-HIV (vCP1452) uses a canarypox virus with man-made parts of HIV attached to it. The canarypox virus cannot cause disease in people. LIPO-5 is a mixture of five man-made proteins similar to proteins found in HIV. These vaccines are not produced from live HIV or from infected cells and do not contain the virus. It is not possible to become infected with HIV from these vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsANRS, Emerging Infectious Diseases

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 14, 2004
Enrollment StartMar 1, 2004
Study CompletionMar 1, 2007
TodayJul 2, 2026
Posted 22.5 years ago

Interventions

ALVAC-HIV (vCP1452)biological

experimental vaccine

LIPO-5biological

experimental vaccine